Gene expression of sternohyoid and diaphragm muscles in type 2 diabetic rats

BMC Endocrine Disorders

Volumn 13, Issue , 2013, Pages

  Van Lunteren, Erik ^a,b,c   Moyer, Michelle ^a  

^a Biomedical Research Bldg   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; OXIDOREDUCTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREATHING MUSCLE; CALCIUM TRANSPORT; CARBOHYDRATE METABOLISM; CIRCULATION; CONTROLLED STUDY; DIAPHRAGM MUSCLE; ENZYME ACTIVITY; GENE EXPRESSION; IMMUNE RESPONSE; INFLAMMATION; ION TRANSPORT; LIPID METABOLISM; MALE; MUSCLE CONTRACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; STERNOHYOID MUSCLE; STRESS; WOUND;

EID: 84884996865     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-13-43     Document Type: Article

References (93)

1. Almeida S, Riddell MC, Cafarelli E. Slower conduction velocity and motor unit discharge frequency are associated with muscle fatigue during isometric exercise in type 1 diabetes mellitus. Muscle Nerve 2008, 37:231-240. 10.1002/mus.20919, 18041050.
2. Cotter M, Cameron NE, Lean DR, Robertson S. Effects of long-term streptozotocin diabetes on the contractile and histochemical properties of rat muscles. Q J Exp Physiol 1989, 74:65-74.
3. McGuire M, MacDermott M. The influence of streptozotocin-induced diabetes and the antihyperglycaemic agent metformin on the contractile characteristics and the membrane potential of the rat diaphragm. Exp Physiol 1998, 83:481-487.
4. Scano G, Filippelli M, Romagnoli I, Mancini M, Misuri G, Duranti R, Rosi E. Hypoxic and hypercapnic breathlessness in patients with type I diabetes mellitus. Chest 2000, 117:960-967. 10.1378/chest.117.4.960, 10767225.
5. Wanke T, Formanek D, Auinger M, Popp W, Zwick H, Irsigler K. Inspiratory muscle performance and pulmonary function changes in insulin-dependent diabetes mellitus. Am Rev Resp Dis 1991, 143:97-100. 10.1164/ajrccm/143.1.97, 1986691.
6. Wanke T, Lahrmann H, Auinger M, Merkle M, Formanek D, Ogris E, Irsigler K, Zwick H. Endogenous opiod system during inspiratory loading in patients with type 1 diabetes. Am Rev Respir Dis 1993, 148:1335-1340. 10.1164/ajrccm/148.5.1335, 8239172.
7. McGuire M, Dumbleton M, MacDermott M, Bradford A. Contractile and electrical properties of sternohyoid muscle in streptozotocin diabetic rats. Clin Exp Pharmacol Physiol 2001, 28:184-187. 10.1046/j.1440-1681.2001.03433.x, 11207673.
8. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004, 18:39-51. 10.1096/fj.03-0610com, 14718385.
9. Sreekumar R, Halvatsiotis P, Schimke JC, Nair KS. Gene expression profile in skeletal muscle of type 2 diabetes and the effect of insulin treatment. Diabetes 2002, 51:1913-1920. 10.2337/diabetes.51.6.1913, 12031981.
10. Suh YH, Kim Y, Bang JH, Choi KS, Lee JW, Kim WH, Oh TJ, An S, Jung MH. Analysis of gene expression profiles in insulin-sensitive tissues from pre-diabetic and diabetic Zucker diabetic fatty rats. J Mol Endocrinol 2005, 34:299-315. 10.1677/jme.1.01679, 15821098.
11. Voss MD, Beha A, Tennagels N, Tschank G, Herling AW, Quint M, Gerl M, Metz-Weidmann C, Haun G, Korn M. Gene expression profiling in skeletal muscle of Zucker diabetic fatty rats: implications for a role of stearoyl-CoA desaturase 1 in insulin resistance. Diabetologia 2005, 48:2622-2630. 10.1007/s00125-005-0025-2, 16284748.
12. van Lunteren E, Moyer M. Gene expression profiling in the type 1 diabetes rat diaphragm. PLoS One 2009, 4:E7832. 10.1371/journal.pone.0007832, 2773011, 19915678.
13. van Lunteren E, Spiegler S, Moyer M. Differential expression of lipid and carbohydrate metabolism genes in upper airway versus diaphragm muscle. Sleep 2010, 33:363-370. 2831431, 20337195.
14. van Lunteren E, Moyer M. Oxidoreductase, morphogenesis, extracellular matrix and calcium ion binding gene expression in streptozotocin-induced diabetic rat heart. Am J Physiol Endocrinol Metab 2007, 293:E759-E768. 10.1152/ajpendo.00191.2007, 17566115.
15. van Lunteren E, Moyer M. Altered diaphragm action potentials in Zucker diabetic fatty (ZDF) rats. Respir Physiol Neurobiol 2006, 153:157-165. 10.1016/j.resp.2005.09.015, 16311078.
16. van Lunteren E, Spiegler S, Moyer M. Contrast between cardiac left ventricle and diaphragm muscle in expression of genes involved in carbohydrate and lipid metabolism. Respir Physiol Neurobiol 2008, 161:41-53. 10.1016/j.resp.2007.11.005, 18207466.
17. Ishwaran H, Rao JS. Detecting differentially expressed genes in microarrays using Bayesian model selection. J Am Stat Assoc 2003, 98:438-455.
18. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: data base for annotation, visualization, and integrated discovery. Genome Biol 2003, 4:R60.
19. Hosack DA, Dennis G, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003, 4:R70. 10.1186/gb-2003-4-10-r70, 328459, 14519205.
20. Beatty CH, Peterson RD, Bocek RM, West ES. Acetoacetate and glucose uptake by diaphragm and skeletal muscle from control and diabetic rats. J Biol Chem 1959, 234:11-15.
21. Beloff-Chain A, Chain EB, Rookledge KA. The influence of insulin and of contraction on glucose metabolism in the perfused diaphragm muscle from normal and streptozotocin-treated rats. Biochem J 1971, 125:97-103. 1178029, 5158926.
22. Beloff-Chain A, Rookledge KA. The metabolism of glucose in diaphragm muscle from normal rats, from streptozotocin-treated diabetic rats and from rats treated with anti-insulin serum. Biochem J 1968, 110:529-532. 1187382, 5701683.
23. Caterson ID, Fuller SJ, Randle PJ. Effect of the fatty acid oxidation inhibitor 2-tetradecylglycidic acid on pyruvate dehydrogenase complex activity in starved and alloxan-diabetic rats. Biochem J 1982, 208:53-60. 1153928, 7159398.
24. Foster JM, Villee CA. Pyruvate and acetate metabolism in the isolated rat diaphragm. J Biol Chem 1954, 211:797-808.
25. Garland PB, Newsholme EA, Randle PJ. Regulation of glucose uptake by muscle. 9. Effects of fatty acids and ketone bodies, and of alloxan-diabetes and starvation, on pyruvate metabolism and on lactate-pyruvate and L-glycerol 3-phosphate-dihydroxyacetone phosphate concentration ratios in rat heart and rat diaphragm muscles. Biochem J 1964, 93:665-678. 1214025, 4284560.
26. Ianuzzo CD, Noble EG, Hamilton N, Dabrowski B. Effects of streptozotocin diabetes, insulin treatment, and training on the diaphragm. J Appl Physiol 1982, 52:1471-1475.
27. Randle PJ, Newsholme EA, Garland PB. Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J 1964, 93:652-665. 1214024, 4220952.
28. Chorváthová V, Ondreicka R, Ozdin L, Dzúrik R. Metabolism of palmitate-1-14C in the tissues of rats with streptozotocin diabetes. Physiol Bohemoslov 1981, 30:259-266.
29. Garland PB, Randle PJ. Regulation of glucose uptake by muscles. 10. Effects of alloxan-diabetes, starvation, hypophysectomy and adrenalectomy, and of fatty acids, ketone bodies and pyruvate, on the glycerol output and concentrations of free fatty acids, long-chain fatty acyl-coenzyme A, glycerol phosphate and citrate-cycle intermediates in rat heart and diaphragm muscles. Biochem J 1964, 93:678-687. 1214026, 5839199.
30. Stearns SB, Tepperman HM, Tepperman J. Studies on the utilization and mobilization of lipid in skeletal muscles from streptozotocin-diabetic and control rats. J Lipid Res 1979, 20:654-662.
31. Wall SR, Lopaschuk GD. Glucose oxidation rates in fatty acid-perfused isolated working hearts from diabetic rats. Biochim Biophys Acta 1989, 1006:97-103. 10.1016/0005-2760(89)90328-7, 2804076.
32. Gerber LK, Aronow BJ, Matlib MA. Activation of a novel long-chain free fatty acid generation and export system in mitochondria of diabetic rat hearts. Am J Physiol Cell Physiol 2006, 291:1198-1207.
33. Durgan DJ, Smith JK, Hotze MA, Egbejimi O, Cuthbert KD, Zaha VG, Dyck J, Abel ED, Young ME. Distinct transcriptional regulation of long-chain acyl-CoA synthetase isoforms and cytosolic thioesterase 1 in the rodent heart by fatty acids and insulin. Am J Physiol Heart Circ Physiol 2006, 290:H2480-H2497. 10.1152/ajpheart.01344.2005, 16428347.
34. Kahn BB, Alquier T, Carlin D, Hardie DG. AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metabol 2005, 1:15-25.
35. Kinlaw WB, Quinn JL, Wells WA, Roser-Jones C, Moncur JT. Minireview: spot 14: a marker of aggressive breast cancer and a potential therapeutic target. Endocrinology 2006, 147:4048-4055. 10.1210/en.2006-0463, 16809441.
36. LaFave LT, Augustin LB, Mariash CN. Minireview: S14: Insights from knockout mice. Endocrinology 2006, 147:4044-4047. 10.1210/en.2006-0473, 16809440.
37. Bennati AM, Schiavoni G, Franken S, Piobbico D, Della Fazia MA, Caruso D, De Fabiani E, Benedetti L, Cusella De Angelis MG, Gieselmann V, Servillo G, Beccari T, Roberti R. Disruption of the gene encoding 3β-hydroxysterol Δ14-reductase (Tm7sf2) in mice does not impair cholesterol biosynthesis. FEBS J 2008, 275:5034-5047. 10.1111/j.1742-4658.2008.06637.x, 18785926.
38. Osmundsen H, Bjørnstad K. Inhibitory effects of some long-chain unsaturated fatty acids on mitochondrial β-oxidation. Biochem J 1985, 230:329-337. 1152622, 4052049.
39. Arikawa E, Ma RCW, Isshiki K, Luptak I, He Z, Yasuda Y, Maeno Y, Patti ME, Weir GC, Harris RA, Zammit VA, Tian R, King GL. Effects of insulin replacements, inhibitors of angiotensin, and PKCβ's actions to normalize cardiac gene expression and fuel metabolism in diabetic rats. Diabetes 2007, 56:1410-1420. 10.2337/db06-0655, 17363743.
40. Mishra R, Emancipator SN, Miller C, Kern T, Simonson MS. Adipose differentiation-related protein and regulators of lipid homeostasis identified by gene expression profiling in the murine db/db diabetic kidney. Am J Physiol Renal Physiol 2004, 286:913-921.
41. Nordström EA, Rydén M, Backlund EC, Dahlman I, Kaaman M, Blomqvist L, Cannon B, Nedergaard J, Arner P. A human-specific role of celldeath-inducing DFFA (DNA fragmentation factor-α)-like effector A (CIDEA) in adipocyte lipolysis and obesity. Diabetes 2005, 54:1726-1734. 10.2337/diabetes.54.6.1726, 15919794.
42. Zhou Z, Toh SY, Chen Z, Guo K, Ng CP, Ponniah S, Lin S-C, Hong W, Li P. Cidea-deficient mice have lean phenotype and are resistant to obesity. Nat Genet 2003, 35:49-56.
43. Carey AL, Petersen EW, Bruce CR, Southgate RJ, Pilegaard H, Hawley JA, Pedersen BK, Febbraio MA. Discordant gene expression in skeletal muscle and adipose tissue of patients with type 2 diabetes: effect of interleukin-6 infusion. Diabetologia 2006, 49:1000-1007. 10.1007/s00125-006-0178-7, 16538490.
44. Depre C, Young ME, Ying J, Ahuja HS, Han Q, Garza N, Davies PJA, Taegtmeyer H. Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. J Mol Cell Cardiol 2000, 32:985-996. 10.1006/jmcc.2000.1139, 10888252.
45. Stavinoha MA, RaySpellicy JW, Essop MF, Graveleau C, Abel ED, Hart-Sailors ML, Mersmann HJ, Bray MS, Young ME. Evidence for mitochondrial thioesterase 1 as a peroxisome proliferators-activated receptor-α-regulated gene in cardiac and skeletal muscle. Am J Physiol Endocrinol Metab 2004, 287:888-895.
46. Chiu H-C, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, Yamada KA, Brunet S, Xu H, Nernonne JM, Welch MJ, Fettig NM, Sharp TL, Sambandam N, Olson KM, Ory DS, Schaffer JE. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 2005, 96:225-233. 10.1161/01.RES.0000154079.20681.B9, 15618539.
47. James DE, Brown R, Navarro J, Pilch PF. Insulin-regulatable tissues express a unique insulin-sensitive glucose transport protein. Nature 1988, 333:183-185. 10.1038/333183a0, 3285221.
48. Shoghi KI, Gropler RJ, Sharp T, Herrero P, Fettig N, Su Y, Mitra MS, Kovacs A, Finck BN, Welch MJ. Time course of alterations in myocardial glucose utilization in the zucker diabetic fatty rat with correlation to gene expression of glucose transporters: a small-animal PET investigation. J Nucl Med 2008, 49:1320-1327. 10.2967/jnumed.108.051672, 2857655, 18632819.
49. Gaster M, Staehr P, Beck-Nielsen H, Schroder HD, Handberg A. Glut3 is reduced in slow muscle fibers of type 2 diabetic patients: is insulin resistance in type 2 diabetes a slow type 1 fiber disease?. Diabetes 2001, 50:1324-1329. 10.2337/diabetes.50.6.1324, 11375332.
50. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293:1673-1677. 10.1126/science.1061620, 11533494.
51. Meng M, Geisler M, Johansson H, Harholt J, Scheller HV, Mellerowicz EJ, Kleczkowski LA. UDP-glucose pyrophosphorylase is not rate limiting, but is essential in arabidopsis. Plant Cell Physiol 2009, 50:998-1011. 10.1093/pcp/pcp052, 19366709.
52. Sudo T, Ishii A, Asami J, Uematsu Y, Saitoh M, Nakamura A, Tada N, Ohnuki T, Komurasaki T, Nakagawa J. Transgenic mice over-expressing dicarbonyl/L-xylulose reductase gene crossed with KK-Ay diabetic model mice: an animal model for the metabolism of renal carbonyl compounds. Exp Anim 2005, 54:385-394. 10.1538/expanim.54.385, 16365515.
53. Hue L, Rider MH. Role of fructose-2,6-bisphosphate in the control of glycolysis in mammalian tissues. Biochem J 1987, 245:313-324. 1148124, 2822019.
54. Okar DA, Manzano A, Navarro-Sabate A, Riera L, Bartrons R, Lange AJ. PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphate. Trends Biochem Sci 2001, 26:30-35. 10.1016/S0968-0004(00)01699-6, 11165514.
55. Pilkis SJ, Claus TH, Kurland IJ, Lange AJ. 6-Phosphofructro-2-kinase/ fructose-2,6-bisphosphate: a metabolic signaling enzyme. Annu Rev Biochem 1995, 64:799-835. 10.1146/annurev.bi.64.070195.004055, 7574501.
56. van Schaftingen E. Fructose 2,6-bisphosphate. Adv Enzymol Relate Areas Mol Biol 1987, 59:315-395.
57. Wu C, Khan SA, Peng L-J, Lange AJ. Roles for fructose-2,6-bisphosphate in the control of fuel metabolism: beyond its allosteric effects on glycolytic and gluconeogenic enzymes. Advan Enzyme Regul 2006, 46:72-88.
58. Lehti TM, Silvennoinen M, Kivelä R, Kainulainen H, Komulainen J. Effects of streptozotocin-induced diabetes and physical training on gene expression of titin-based stretch-sensing complexes in mouse striated muscle. Am J Physiol Endocrinol Metab 2007, 292:E533-E542.
59. Endo T, Onaya T. Parvalbumin is reduced in the peripheral nerves of diabetic rats. J Clin Invest 1986, 78:1161-1164. 10.1172/JCI112697, 423799, 3771787.
60. Haghighi K, Chen G, Sato Y, Fan GC, Kolokathis F, Pater L, Paraskevaidis I, Jones WK, Dorn GW, Kremastinos DT, Kranias EG. A human phospholamban promoter polymorphism in dilated cardiomyopathy alters transcriptional regulation by glucocorticoids. Human Mutat 2008, 29:640-647.
61. Kim HW, Ch YS, Lee HR, Park SY, Kim YH. Diabetic alterations in cardiac sarcoplasmic reticulum Ca2+-ATPase and phospholamban protein expression. Life Sci 2001, 70:367-379. 10.1016/S0024-3205(01)01483-7, 11798007.
62. Zhong Y, Ahmed S, Grupp IL, Matlib MA. Altered SR protein expression associated with contractile dysfunction in diabetic rat hearts. Am J Physiol Heart Circ Physiol 2001, 281:1137-1147.
63. Vasanji Z, Dhalla NS, Netticadan T. Increased inhibition of SERCA2 by phospholamban in the type I diabetic heart. Mol Cell Biochem 2004, 261:245-249.
64. Alzugaray ME, García M, Del Zotto HH, Raschia MA, Palomeque J, Rossi J, Gagliardino JJ, Flores LE. Changes in islet plasma membrane calcium-ATPase activity and isoform expression induced by insulin resistance. Arch Biochem Biophys 2009, 490:17-23. 10.1016/j.abb.2009.07.022, 19653992.
65. Wieteska-Skrzeczynska W, Grzelkowska-Kowalczyk K, Jank M, Maciejewski H. Transcriptional dysregulation of skeletal muscle protein metabolism in streptozotocin-diabetic mice. J Physiol Pharmacol Suppl 2009, 1:29-39.
66. Nairn AC, Bhagat B, Palfrey HC. Identification of calmodulin-dependent protein kinase III and its major Mr 100,000 substrate in mammalian tissues. Proc Natl Acad Sci U S A 1985, 82:7939-7943. 10.1073/pnas.82.23.7939, 390885, 3906654.
67. Redpath NT, Proud CG. Purification and phosphorylation of elongation factor-2 kinase from rabbit reticulocytes. Eur J Biochem 1993, 212:511-520. 10.1111/j.1432-1033.1993.tb17688.x, 8444188.
68. Ryazanov AG, Natapov PG, Shestakova EA, Severin FF, Spirin AS. Phosphorylation of elongation factor 2: the fifth Ca2+/calmodulin-dependent system of protein phosphorylation. Biochimie (Paris) 1988, 70:619-626.
69. Fukaya N, Mochizuki K, Shimada M, Goda T. The α-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes. Nutrition 2009, 25:657-667. 10.1016/j.nut.2008.11.015, 19216056.
70. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ulrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM. Cell-surface calretuculin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005, 123:321-334. 10.1016/j.cell.2005.08.032, 16239148.
71. Strickland DK, Gonias SL, Argraves WS. Diverse roles for the LDL receptor family. Trends Endocrinol Metab 2002, 13:66-74. 10.1016/S1043-2760(01)00526-4, 11854021.
72. Baelde HJ, Eikmans M, Doran PP, Lappin DW, de Herr E, Bruijn JA. Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis 2004, 43:636-650. 10.1053/j.ajkd.2003.12.028, 15042541.
73. Leung JC, Chan LY, Tsang AW, Tang SC, Lai KN. Differential expression of aquaporins in the kidneys of streptozotocin-induced diabetic mice. Nephrology (Carlton) 2005, 10:63-72.
74. Dt W, Yau SK, Mee AP, Mawer EB, Miller CA, Garland HO, Riccardi D. Functional, molecular, and biochemical characterization of streptozotocin-induced diabetes. J Am Soc Nephrol 2001, 12:779-790.
75. Lee JE, Lee JS, Hwang SH. Microarray for genes associated with signal transduction in diabetic OLETF keratocytes. Korean J Ophthalmol 2007, 21:111-119. 10.3341/kjo.2007.21.2.111, 2629708, 17592243.
76. Nielsen JM, Kristiansen SB, Nørregaard R, Andersen CL, Denner L, Nielsen TT, Flyvbjerg A, Bøtker HE. Blockage of receptor for advanced glycation end products prevents development of cardiac dysfunction in db/db type 2 diabetic mice. Eur J Heart Fail 2009, 11:638-647. 10.1093/eurjhf/hfp070, 19502378.
77. Fowlkes JL, Bunn RC, Liu L, Wahl EC, Coleman HN, Cockrell GE, Perrien DS, Lumpkin CK, Thrailkill KM. Runt-related transcription factor 2 (RUNX2) and RUNX2-related osteogenic genes are down-regulated throughout osteogenesis in type 1 diabetes mellitus. Endocrinology 2008, 149:1697-1704. 10.1210/en.2007-1408, 2276714, 18162513.
78. Ladeiras-Lopes R, Ferreira-Martins J, Leite-Moreira AF. The apelinergic system: the role played in human physiology and pathology and potential therapeutic applications. Arq Bras Cardiol 2008, 90:343-349.
79. Erdeem G, Dogru T, Tasci I, Sonmex A, Tapan S. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008, 116:289-292. 10.1055/s-2007-1004564, 18484561.
80. Zhang Y, Shen C, Li X, Ren G, Fan X, Ren F, Zhang N, Sun J, Yang J. Low plasma apelin in newly diagnosed type 2 diabetes in Chinese people. Diabetes Care 2009, 32:e150. 10.2337/dc09-1146, 19940213.
81. Li L, Yang G, Li Q, Tang Y, Yang M, Yang H, Li K. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006, 114:544-548. 10.1055/s-2006-948309, 17177135.
82. Kobori M, Masumoto S, Akimoto Y, Takahashi Y. Dietary quercetin alleviates diabetic symptoms and reduces streptozotocin-induced disturbance of hepatic gene expression in mice. Mol Nutr Food Res 2009, 53:859-868. 10.1002/mnfr.200800310, 19496084.
83. Maresh JG, Shohet RV. In vivo endothelial gene regulation in diabetes. Cardiovasc Diabetol 2008, 7:8. 10.1186/1475-2840-7-8, 2365940, 18423039.
84. Flier JS, Cook KS, Usher P, Spiegelman BM. Severely impaired adipsin expression in genetic and acquired obesity. Science 1987, 237:405-408. 10.1126/science.3299706, 3299706.
85. Hershenson MB. p21waf-1/Cip-1and the prevention of oxidative stress. Am J Physiol Lung Cell Mol Physiol 2004, 286:L502-L505. 10.1152/ajplung.00336.2003, 14761871.
86. Lunz JG, Tsuji H, Nozaki I, Murase N, Demetris AJ. An inhibitor of cyclin-dependent kinase, stress-induced p21waf-1/Cip-1, mediates hepatocyte mito-inhibition during the evolution of cirrhosis. Hepatology 2005, 41:1262-1271. 10.1002/hep.20709, 15880761.
87. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999, 85:9-24. 10.1016/S0167-0115(99)00089-0, 10588446.
88. Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, Sposato I, Cremasco F, Ognibene A, Rotella C. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005, 48:1168-1172. 10.1007/s00125-005-1749-8, 15864535.
89. Ryskjaer J, Deacon CF, Carr RD, Krarup T, Madsbad S, Holst J, Vilsboll T. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol 2006, 155:485-493. 10.1530/eje.1.02221, 16914604.
90. McKillop AM, Duffy NA, Lindsay JR, O'Harte FRM, Bell PM, Flatt PR. Decreased dipeptidyl peptidase-IV activity and glucagons-like peptide-1 (7-36) amide degradation in type 2 diabetic subjects. Diabetes Res Clin Pract 2008, 79:79-85. 10.1016/j.diabres.2007.08.001, 17904681.
91. Meneilly GS, Demuth HU, McIntosh CHS, Pederson RA. Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidylpeptidase IV responses to oral glucose. Diabet Med 2000, 17:346-350. 10.1046/j.1464-5491.2000.00236.x, 10872532.
92. Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K, Nakahori Y. Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol 2009, 200:53-61. 10.1677/JOE-08-0424, 18931022.
93. Knoll KE, Pietrusz JL, Liang M. Tissue-specific transcriptome responses in rats with early streptozotocin-induced diabetes. Physiol Genomics 2002, 21:222-229.